Immunohistochemical Biomarkers in Breast Cancer

References

• Osborne CK, Clark GM, Ravdin PM: Adjuvant systemic therapy of primary breast cancer. In Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (eds). Lippincott-Raven, 1996, pp 548–578
   Google Scholar
• Clark GM: Prognostic and predictive factors. In Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (eds). Lippincott-Raven Publishers, Philadelphia, 1996, pp 199–215
   Google Scholar
• ASCO Expert Panel: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793-795, 1998
   Google Scholar
• Henson DE, Fielding P, Grignon DJ et al: College of Ameri-can Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 119:1109–1112, 1994
   Web of Science ®Google Scholar
• Hayes DF, Bast R, Desch CE et al: A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456–1466, 1996
   PubMed Web of Science ®Google Scholar
• Allred DC, Harvey JM, Berardo M et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168, 1998
   PubMed Web of Science ®Google Scholar
• DeSombre ER, Thorpe SM, Rose C et al: Prognostic useful-ness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res (Suppl) 46:4256s–4264s, 1986
   PubMedGoogle Scholar
• Walker KJ, Bouzubar N, Robertson J et al: Immunocyto-chemical localization of estrogen receptor in human breast tissue. Cancer Res 48:6517–6522, 1988
   PubMed Web of Science ®Google Scholar
• Kinsel LB, Szabo E, Greene GL et al: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative bio-chemical methods. Cancer Res 49:1052–1056, 1989
   PubMed Web of Science ®Google Scholar
• Pertschuk LP, Kim DS, Nayer K et al: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine re-sponse and survival. Cancer 66:1663–1670, 1990
   PubMed Web of Science ®Google Scholar
• Reiner A, Neumeister B, Spona J et al: Immunocytochemical localization of estrogen and progesterone receptor and prog-nosis in human primary breast cancer. Cancer Res 50:7057–7061, 1990
   PubMed Web of Science ®Google Scholar
• Andersen J, Thorpe SM, King WJ et al: The prognostic value of immunohistochemical estrogen receptor analysis in paraf-fin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 26:442–449, 1990
   PubMed Web of Science ®Google Scholar
• Cowen PN, Teasdale J, Jackson P etal: Oestrogen receptor in breast cancer: prognostic studies using a new immunohisto-chemical assay. Histopathology 17:319–325, 1990
   PubMedGoogle Scholar
• Seymour L, Meyer K, Esser J et al: Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods. Am J Clin Pathol 94 (Suppl):S35—S40, 1990
   Google Scholar
• Andersen I, Thorpe SM, Rose C et al: Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated char-coal assay. Acta Oncol 30:685–690, 1991
   PubMed Web of Science ®Google Scholar
• Querzoli P, Ferretti S, Marzola A et al: Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer. Twnori 78(5):287–290, 1992
   Google Scholar
• Robertson JFR, Bates K, Pearson D et al: Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 65(5):727–730, 1992
   PubMed Web of Science ®Google Scholar
• Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, pro-gesterone receptor, p52, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239–248, 1993
   PubMedGoogle Scholar
• Battifora H, Mehta P, Ahn C et al: Estrogen receptor immu-nohistochemical assay-in paraffin-embedded tissue. A better gold standard? Appl Itnmunohistochem 1(1):39–45, 1993
   Google Scholar
• Hanna W, McReady DR, Chapman JW et al: The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis. Mod Pathol 6(6):748–754, 1993
   PubMed Web of Science ®Google Scholar
• Esteban JM, Ahn C, Mehta P et al: Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 102: 158–162, 1994
   PubMed Web of Science ®Google Scholar
• Kommoss F, Pfisterer J, Idris T et al: Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Analyst Quant Cytol Histol 16:203–210, 1994
   PubMed Web of Science ®Google Scholar
• Beck T, Weikel W, Brumm C et al: Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): Prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC). Gynecol Oncol 53:220–227, 1994
   PubMed Web of Science ®Google Scholar
• Stierer M, Rosen H, Weber R et al: A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 36:11–21, 1995
   PubMed Web of Science ®Google Scholar
• Ferrer Roca O, Ramos A, Diaz Cardama A: Immunohisto-chemical correlation of steroid receptors and disease-free in-terval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation. Ana-lyst Cell Pathol 9:151–163, 1995
   PubMedGoogle Scholar
• Ferno M, Andersson C, Fallenius G et al: Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. Acta Oncol 35:17–22, 1996
   PubMed Web of Science ®Google Scholar
• Veronese SM, Barbareschi M, Morelli L et al: Predictive value of ER1D5 antibody immunostaining in breast cancer: A paraffin-based retrospective study of 257 cases. App Im-munohistochem 3(2):85–90, 1995
   Google Scholar
• Molino A, Micciolo R, Turazza M et al: Prognostic signifi-cance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical meth-ods. Breast Cancer Res Treat 43(3):221–228, 1997
   Google Scholar
• McCarty KSJ, Miller LS, Cox EB et al: Estrogen receptor analysis. Correlation of biochemical and immunohistochem-ical methods using monoclanal antireceptor antibodies. Arch Pathol Lab Med 109:716–721, 1985
   PubMed Web of Science ®Google Scholar
• Pertschuk LP, Eisenberg KB, Carter AC et al: Immunohis-tologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer 55:1513–1518, 1985
   PubMed Web of Science ®Google Scholar
• Ozzello L, De Rose C, Habif DV et al: Immunostaining of estrogen receptors in paraffin sections of breast cancers using anti-estrophilin monoclonal antibodies. In Monoclonal Anti-bodies in Breast Cancer, Ceriani R (ed). Martinus Hijhoff Publishers, Boston, 1985, pp 312–254
   Google Scholar
• Jonat W, Maass H, Stegner HE: Immunohistochemical mea-surement of estrogen receptors in breast cancer tissue samples. Cancer Res 46 (Suppl):4296s-4298s, 1986
   PubMedGoogle Scholar
• McClelland RA, Berger U, Miller LS et al: Immunocyto-chemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 46 (Suppl):4241s-4243s, 1986
   PubMedGoogle Scholar
• Berger U, Mansi JL, Wilson P et al: Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. J Clin Oncol 5:1779–1782, 1987
   PubMed Web of Science ®Google Scholar
• Burton GV, Flowers JL, Cox EB et al: Estrogen receptor determination by monoclonal antibody in fine needle aspira-tion breast cancer cytologies: A marker of hormone response. Breast Cancer Res Treat 10:287–291, 1987
   PubMed Web of Science ®Google Scholar
• Coombes RC, Berger U, McClelland RA et al: Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lan-cet ii 701–703, 1987
   Google Scholar
• De Lena M, Marzullo F, Simone G et al: Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer. Oncology 45:308–312, 1988
   PubMed Web of Science ®Google Scholar
• Andersen J, Poulsen HS: Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical en-docrine response. J Steroid Biochem 30:337–339, 1988
   PubMedGoogle Scholar
• Hawkins RA, Sangster K, Tesdale A et al: The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer; correlation with biochemical assay and predic-tion of response to endocrine therapy. Br J Cancer 58:77–80, 1988
   PubMed Web of Science ®Google Scholar
• Gaskell DJ, Hawkins RA, Sangsteri K et al: Relation be-tween immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1:1044–1046, 1989
   PubMed Web of Science ®Google Scholar
• Andersen J, Poulsen HS: Immunohistochemical estrogen re-ceptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 64:1901–1908, 1989
   PubMed Web of Science ®Google Scholar
• Sklarew RJ, Bodmer SC, Pertschuk LP: Quantitative imag-ing of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry 11:359–378, 1990
   PubMedGoogle Scholar
• McClelland RA, Finlay P, Walker KJ et al: Automated quan-titation of immunocytochemically localized estrogen recep-tors in human breast cancer. Cancer Res 50:3545–3550, 1990
   PubMed Web of Science ®Google Scholar
• Goulding H, Pinder S, Cannon R et al: A new immunohis-tochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Human Pathol 26:291–294, 1995
   PubMed Web of Science ®Google Scholar
• Pertschuk LP, Feldman JG, Kim Y-D et al: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more ac-curately than H222Sp-y in frozen sections or cytosol-based ligand-binding assays. Cancer 77:2514–2519, 1996
   PubMed Web of Science ®Google Scholar
• Barnes DM, Harris WH, Smith P et al: Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clini-cal outcome of breast cancer patients. Br J Cancer 74:1445–1451, 1996
   PubMed Web of Science ®Google Scholar
• Harvey JM, Clark GM, Osborne CK et al: Estrogen receptor status by immunohistochemistry is superior to the ligand binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481, 1999
   PubMed Web of Science ®Google Scholar
• Layfield Li, Saria EA, Conlon DH et al: Estrogen and pro-gesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prog-nostic significance. J Surg Oncol 61:177–184, 1996
   PubMed Web of Science ®Google Scholar
• Pertschuk LP, Feldman JG, Eisenberg KB et al: Immunocy-tochemical detection of progesterone receptor in breast can-cer with monoclonal antibody. Relation to biochemical as-say, disease-free survival, and clinical endocrine response. Cancer 62:342–349, 1988
   PubMed Web of Science ®Google Scholar
• Gasparini G, Pozza F, Dittadi R et al: Progesterone receptor determined by immunocytochemical and biochemical meth-ods in human breast cancer. J Cancer Res Clin Oncol 118: 557–563, 1992
   PubMed Web of Science ®Google Scholar
• Muller-Holzner E, Zeimet AG, Daxenbichler G et al: Pro-gesterone receptors in routinely paraffin-embedded primary breast carcinomas and lymph node metastases. Breast Can-cer Res Treat 25:47–55, 1993
   PubMed Web of Science ®Google Scholar
• Tandon AK, Clark GM, Chamness GC et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin On-col 7:1120–1128, 1989
   PubMed Web of Science ®Google Scholar
• Allred DC, Clark GM, Tandon AK et al: HER-2/neu in node-negative breast cancer: prognostic significance of overex-pression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599–605, 1992
   PubMed Web of Science ®Google Scholar
• Bianchi S, Paglierani M, Zampi G et al: Prognostic signifi-cance of c-erbB-2 expression in node-negative breast cancer. Br J Cancer 67:625–629, 1993
   PubMed Web of Science ®Google Scholar
• Borg A, Tandon AK, Sigurdsson H et al: HER-2/neu ampli-fication predicts poor survival in node-positive breast cancer. Cancer Res 50:4332–4337, 1990
   PubMed Web of Science ®Google Scholar
• Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944–948, 1991
   PubMed Web of Science ®Google Scholar
• Lovekin C, Ellis JO, Locker A et al: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Can-cer 63:439–443, 1991
   PubMed Web of Science ®Google Scholar
• McCann AH, Dervan PA, O’Regan M et al: Prognostic sig-nificance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51:3296–3303, 1991
   PubMed Web of Science ®Google Scholar
• Noguchi M, Koyasaki N, Ohta N et al: c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 69:2953–2960, 1992
   PubMed Web of Science ®Google Scholar
• O’Reilly SM, Barnes DM, Camplejohn RS et al: The rela-tionship between c-erbB-2 expression, S-phase fraction, and prognosis in breast cancer. Br J Cancer 63:444–446, 1991
   PubMed Web of Science ®Google Scholar
• Paterson MC, Dietrich KD, Kanyluk J et al: Correlation be-tween c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 54:556–567, 1991
   Google Scholar
• Rosen PP, Lesser ML, Arroyo CD et al: Immunohistochem-ical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. Cancer 75(6):1320–1326, 1995
   PubMed Web of Science ®Google Scholar
• Toikkanen S, HelM H, Isola J et al: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10:1044–1048, 1992
   PubMed Web of Science ®Google Scholar
• Albanell J, Bellmunt J, Molina R et al: Node-negative breast cancers with p53(—)/HER2-neu(—) status may identify women with very good prognosis. Anticancer Res 16:1027–1032, 1996
   PubMed Web of Science ®Google Scholar
• Dykins R, Corbett IP, Henry JA et al: Long-term survival in breast cancer related to overexpression of the c-erbB-2 on-coprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 163:105–110, 1991
   PubMed Web of Science ®Google Scholar
• Giai M, Roagna R, Ponzone R et al: Prognostic and predic-tive relevance of c-erbB-2 and ras expression in node posi-tive and negative breast cancer. Anticancer Res 14:1441–1450, 1994
   PubMed Web of Science ®Google Scholar
• Gusterson BA, Gelber RD, Goldhirsch A et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049–1056, 1992
   PubMed Web of Science ®Google Scholar
• Kallioniemi O-P, Holli K, Visakorpi T et al: Association of c-erbB-2 protein over-expression with high rate of cell pro-liferation, increased risk of visceral metastasis, and poor long-term survival in breast cancer. Int J Cancer 49:650–655, 1991
   PubMed Web of Science ®Google Scholar
• Marks JR, Humphrey PA, Wu K et al: Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 219(4):332–341, 1994
   PubMed Web of Science ®Google Scholar
• Press MF, Pike MC, Chazin VR et al: Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpres-sion with increased risk of recurrent disease. Cancer Res 53:4960–4970, 1993
   PubMed Web of Science ®Google Scholar
• Quenel N, Wafflart J, Bonichon F et al: The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 35:283–291, 1995
   PubMed Web of Science ®Google Scholar
• Rilke F, Colnaghi MI, Cascinelli N et al: Prognostic signifi-cance of HER-2/neu expression in breast cancer and its re-lationship to other prognostic factors. Int J Cancer 49:44’19, 1991
   Google Scholar
• Seshadri R, Firgaira FA, Horsfall DJ et al: Clinical signifi-cance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 11:1936–1942, 1993
   PubMed Web of Science ®Google Scholar
• Winstanley J, Cooke T, Murray GD et al: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63:447–450, 1991
   PubMed Web of Science ®Google Scholar
• Paik S, Hazan R, Fisher ER et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112, 1990
   PubMed Web of Science ®Google Scholar
• Anbazhagan R, Gelber RD, Bettelheim R et al: Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 2:47–53, 1991
   PubMed Web of Science ®Google Scholar
• Borg A, Baldetorp B, Ferno M et al: ERBB2 amplification in breast cancer with a high rate of proliferation. Onco gene 6:137–143, 1991
   PubMed Web of Science ®Google Scholar
• Borresen A-L, Ottestad L, Gaustad A et al: Amplification and protein over-expression of the neu/HER-2/c-erbB-2 pro-tooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 62:585–590, 1990
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Ingle JN, Wold LE et al: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 74(11):2956–2963, 1994
   PubMed Web of Science ®Google Scholar
• Muss HB, Thor AD, Berry DA et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260–1266, 1994
   PubMed Web of Science ®Google Scholar
• Schonborn I, Zschiesche W, Spitzer E et al: c-erbB-2 over-expression in primary breast cancer: independent prognostic factor in patients at high risk. Breast Cancer Res Treat 29: 287–295, 1994
   PubMed Web of Science ®Google Scholar
• Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. Can-cer 73:2359–2365, 1994
   Google Scholar
• Battifora H, Gaffey M, Esteban J et al: Immunohistochemical assay of neu/c-erbB -2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective fol-low-up study of 245 stage I and II cases. Mod Pathol 4(4): 466–474, 1991
   PubMed Web of Science ®Google Scholar
• Dati C, Muraca R, Tazartes O et al: c-erbB-2 and ras expres-sion levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47:833–838, 1991
   PubMed Web of Science ®Google Scholar
• Gasparini G, Gullick WJ, Bevilacqua P et al: Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686–695, 1992
   PubMed Web of Science ®Google Scholar
• Gullick WJ, Love SB, Wright C et al:. c-erbB-2 protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:343–438, 1991
   PubMedGoogle Scholar
• Heintz NH, Leslie KO, Rogers LA et al: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114:160–163, 1990
   PubMed Web of Science ®Google Scholar
• Horiguchi J, Iino Y, Takei H et al: Immunohistochemical study on the expression of c-erbB-2 oncoprotein in breast cancer. Oncology 51:47–51, 1994
   PubMed Web of Science ®Google Scholar
• Ji H, Lipponen P, Aaltomaa S et al: c-erbB-2 oncogene re-lated to p53 expression, cell proliferation, and prognosis in breast cancer. Antiean_cer Res 13:1147–1152, 1993
   PubMed Web of Science ®Google Scholar
• Kury R, Sliutz G, Schemper M et al: HER-2 oncogene am-plification and overall survival of breast carcinoma patients. Ear J Cancer 26(9):946–949, 1990
   PubMed Web of Science ®Google Scholar
• Lonn U, Lonn S, Nilsson B et al: Breast cancer: prognostic significance of c-erb-B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clini-copathologcal features. Breast Cancer Res Treat 29:237–245, 1994
   PubMed Web of Science ®Google Scholar
• May E, Mouriesse H, May-Levin F et al: Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 62:430–435, 1990
   PubMed Web of Science ®Google Scholar
• Nagai MA, Marques LA, Torloni H et al: Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50:412–417, 1993
   PubMed Web of Science ®Google Scholar
• Osaki A, Toi M, Yamada H et al: Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 164:323-326, 1992
   PubMed Web of Science ®Google Scholar
• Pierce LJ, Merino MJ, D’Angelo T et al: Is c-erbB2 a pre-dictor for recurrent disease in early stage breast cancer? Int J Radiat Oncol Biol Phys 28:395–403, 1994
   PubMed Web of Science ®Google Scholar
• Schroeter CA, De Potter CR, Rathsmann K et al: c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis. Br J Cancer 66:728–734, 1992
   PubMed Web of Science ®Google Scholar
• Takikawa Y, Noguchi M, Kitagawa H et al: Immunohisto-chemical detection of p53 and c-erbB-2 proteins: prognostic significance in-operable breast cancer. Breast Cancer 1:17-23, 1994
   Google Scholar
• Tsuda H, Hirohashi S, Shimosato Y et al: Immunohistochem-ical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients. Jpn J Cancer Res 81:327–332, 1990
   PubMedGoogle Scholar
• Nakopoulou LL, Alexiadou A, Theodoropoulos GE et al: Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 179:31–38, 1996
   PubMed Web of Science ®Google Scholar
• Tanner B, Friedberg T, Mitze M et al: c-erbB-2 oncogene expression in breast carcinoma: analysis by Si nuclease pro-tection assay and immunohistochemistry in relation to clini-cal parameters. Gynec Oncol 47(2):228–233, 1992
   PubMed Web of Science ®Google Scholar
• Terrier P, Mouriesse H, London B et al: Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer. Acta Oncologica 35(1):23–30, 1996
   PubMed Web of Science ®Google Scholar
• De Placido S, Carlomagno C, De Laurentis M et al: c-erbB-2 expression predicts tamoxifen efficacy in breast cancer pa-tients. Breast Cancer Res Treat 52:145–154, 1998
   Google Scholar
• Pegram MD, Pauletti G, Slamon DJ: HER-2/neu as a pre-dictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:155–167, 1998
   Google Scholar
• Stal O, Sullivan S, Wingren S et al: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31:2185–2190, 1995
   Google Scholar
• Wright C, Nicholson S, Angus B et al: Relationship between c-erbB-2 protein product expression and response to endo-crine therapy in advanced breast cancer. Br J Cancer 65: 118–121, 1992
   PubMed Web of Science ®Google Scholar
• Borg A, Baldetorp B, Ferno M et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor posi-tive breast cancer. Cancer Lett 81:137–144, 1994
   PubMed Web of Science ®Google Scholar
• Carlomagno C, Perrone F, Gallo C et al: c-erbB-2 overex-pression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702–2708, 1996
   PubMed Web of Science ®Google Scholar
• Elledge RM, Green S, Ciocca D et al: Her-2 expression and response to tomaxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group study. Clin Cancer Res 4:7–12, 1998
   PubMed Web of Science ®Google Scholar
• Plunkett TA, Houston SJ, Rubens RD et al: Her-2 over ex-pression is a marker of resistance to endocrine therapy in advanced breast cancer (abstract). Breast Cancer Res Treat 50(3):238 (#109), 1998
   Google Scholar
• Thor AD, Berry DA, Budman DR et al: erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346–1360, 1998
   PubMed Web of Science ®Google Scholar
• Paik S, Bryant J, Park C et al: erbB-2 and response to doxo-rubicin in patients with axillary lymph node-positive, hor-mone receptor-negative breast cancer. J Natl Cancer Inst 90:1361–1370, 1998
   PubMed Web of Science ®Google Scholar
• Colbeigh MA, Vogel CL, Tripathy NJ et al: Efficacy and safety of herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast can-cer. Proc ASCO 17:97a (abstr #376), 1998
   Google Scholar
• Slamon D, Leyland-Jones B, Shak S et al: Addition of her-ceptin (humanized anti-HER2 antibody) to first line chemo-therapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a ran-domized multinational controlled phase III trial. Proc ASCO 17:98a (abstr #377), 1998
   Google Scholar
• Elledge RM, Allred DC: Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat 52: 169–188, 1998
   Google Scholar
• Thor AD, Moore II DH, Edgerton SM et al: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845–855, 1992
   PubMed Web of Science ®Google Scholar
• Isola J, Visakorpi T, HoIli K et al: Association of overex-pression of tumor suppressor protein p53 with rapid cell pro-liferation and poor prognosis in node-negative breast cancer patients. J Nati Cancer Inst 84:1109–1114, 1992
   PubMed Web of Science ®Google Scholar
• Allred DC, Clark GM, Elledge R et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Nazi Can-cer Inst 85:200–206, 1993
   PubMed Web of Science ®Google Scholar
• Noguchi M, Kitagawa H, Kinoshita K et al: Prognostic sig-nificance of p53 and c-erbB-2 expression in operable breast cancer. Int J Clin Oncol 2:587–591, 1993
   Web of Science ®Google Scholar
• Barnes DM, Dublin EA, Fisher Cl et al: Immunohistochem-ical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Human Path 24:469–476, 1993
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Benini E, Daidone MG et al: p53 as an inde-pendent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965–970, 1993
   PubMed Web of Science ®Google Scholar
• Friedrichs K, Gluba S, Eidtmann H et al: Overexpression of p53 and prognosis in breast cancer. Cancer 72:3641–3647, 1993
   PubMed Web of Science ®Google Scholar
• Gasparini G, Bevilacqua P, Boracchi P et al: Prognostic value of p53 expression in early stage breast carcinoma com-pared with tumour angiogenesis, epidermal growth factor receptor, cerbB2, cathepsin D, DNA ploidy, parameters of cell kinetics, and conventional features. Int J Oncol 4:155–162, 1994
   PubMed Web of Science ®Google Scholar
• Elledge RM, Clark GM, Fuqua SAW et al: p53 protein ac-cumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54:3752–3757, 1994
   PubMed Web of Science ®Google Scholar
• Domagala W, Striker G, Szadowska A et al: p53 protein and vimentin in invasive ductal NOS breast carcinoma: relation-ship with survival and sites of metastases. Eur J Cancer 30A:1527–1534, 1994
   PubMed Web of Science ®Google Scholar
• MacGrogan G, Bonichon F, de Mascarel I et al: Prognostic value of p53 in breast invasive ductal carcinoma: an immu-nohistochemical study on 942 cases. Breast Cancer Res Treat 36:71–81, 1995
   PubMed Web of Science ®Google Scholar
• Stenmark-Askmalm M, Stal O, Olsen K et al: p53 as a prog-nostic factor in stage I breast cancer. Br J Cancer 72:715–719, 1995
   PubMed Web of Science ®Google Scholar
• Patel DD, Bhatavdekar JM, Chikhlikar PR et al: Node nega-tive breast carcinoma: hyperprolactinemia and/or overex-pression of p53 as an independent predictor of poor progno-sis compared to newer and established prognosticators. J Surg Oncol 62:86–92, 1996
   PubMed Web of Science ®Google Scholar
• Seshadri R, Leong ASY, McCaul K et al: Relationship be-tween p53 gene abnormalities and other tumour characteris-tics in breast cancer prognosis. Int J Cancer 69:135–141, 1996
   PubMed Web of Science ®Google Scholar
• Visscher DW, Sarkar FH, Wykes S et al: Clinicopathologic significance of p53 immunostaining in adenocarcinoma of the breast. Arch Pathol Lab Med 117:973–976, 1993
   PubMed Web of Science ®Google Scholar
• Gohring UJ, Scharl A, Heckel C et al: p53 protein in 204 patients with primary breast carcinoma—immunohisto-chemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet 256:139–146, 1995
   PubMed Web of Science ®Google Scholar
• Borg A, Lennerstrand J, Stenmark-Askmalm M et al: Prog-nostic significance of p53 overexpression in primary breast cancer: a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer 71:1013–1017, 1995
   PubMed Web of Science ®Google Scholar
• Sawan A, Randall B, Angus B et al: Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 168: 23–28, 1992
   PubMed Web of Science ®Google Scholar
• Andersen TI, Holm R, Nesland JM et al: Prognostic signifi-cance of TP53 alterations in breast carcinoma. Br J Cancer 68:540–548, 1993
   PubMed Web of Science ®Google Scholar
• Lipponen P, Ji H, Aaltomaa S et al: p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 55:51–56, 1993
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Borresen AL, Eyfjord JE: Somatic p53 muta-tions in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 53:1637–1641, 1993
   PubMed Web of Science ®Google Scholar
• Jacquemier J, Moles JP, Penault-Llorca F et al: p53 immu-nohistochemical analysis in breast cancer with four mono-clonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69:846–852, 1994
   PubMed Web of Science ®Google Scholar
• Gasparini G, Weidner N, Bevilacqua P et al: Tumor mi-crovessel density, p53 expression, tumor size, and peritu-moral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454–466, 1994
   PubMed Web of Science ®Google Scholar
• Cunningham JM, Ingle JN, Jung SH et al: p53 gene expres-sion in node-positive breast cancer: relationship to DNA ploidy and prognosis. J Natl Cancer Inst 86:1871–1873, 1994
   PubMed Web of Science ®Google Scholar
• Bergh J, Norberg T, Sjogren S et al: Complete sequencing of the p53 gene provides prognostic information in breast can-1, cer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1:1029–1034, 1995
   PubMed Web of Science ®Google Scholar
• Home GM, Anderson JJ, Tiniakos DG et al: p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73: 29–35, 1996
   PubMed Web of Science ®Google Scholar
• Sjogren S, Inganas M, Norberg T et al: The p53 gene in breast cancer: prognostic value of complementary DNA se-quencing versus immunohistochemistry. J Natl Cancer Inst 88:173–182, 1996
   PubMed Web of Science ®Google Scholar
• Pietilainen T, Lipponen P, Aaltomaa S et al: Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177:225–232, 1995
   PubMed Web of Science ®Google Scholar
• DeWitte HH, Foekens JA, Lennerstrand J et al: Prognostic significance of TP53 accumulation in human primary breast cancer: comparison between a rapid quantitative immunoas-say and SSCP analysis. Int J Cancer 69:125–130, 1996
   PubMed Web of Science ®Google Scholar
• Ostrowski JL, Sawan A, Henry L et al: p53 expression in human breast cancer related to survival and prognostic fac-tors: an immunohistochemical study. J Pathol 164:75–81, 1991
   PubMed Web of Science ®Google Scholar
• Hanzal E, Gitsch G, Kohlberger P et al: Immunohistochem-ical detection of mutant p53 suppressor gene product in pa-tients with breast cancer: influence on metastasis free sur-vival. Anticancer Res 12:2325–2330, 1992
   PubMed Web of Science ®Google Scholar
• Bosari S, Lee AK, Viale G et al: Abnormal p53 immunore-activity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Archiv 421:291–295, 1992
   Web of Science ®Google Scholar
• Poller DN, Hutchings CE, Galea M et al: p53 protein ex-pression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583–588, 1992
   PubMed Web of Science ®Google Scholar
• Wiltschke C, Kindas-Muegge I, Steininger A et al: Coex-pression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 120:737–742, 1994
   PubMed Web of Science ®Google Scholar
• Hurlimann J: Prognostic value of p53 protein expression in breast carcinomas. Pathol Res Practice 189:996–1003, 1993
   PubMed Web of Science ®Google Scholar
• Caleffi M, Teague MW, Jensen RA et al: p53 gene mutations and steroid receptor status in breast cancer. Cancer 73:2147–2156, 1993
   Web of Science ®Google Scholar
• Haerslev T, Jacobsen GK: An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hu-man Pathol 26:295–301, 1995
   PubMed Web of Science ®Google Scholar
• Schonborn I, Minguillon C, Lichtenegger W et al: c-erbB-2, EGF receptor, p53, and PCNA: the prognostic significance of recent tumor markers for lymph node negative breast cancer. Geburtshilfe und Frauenheilkunde 55:566–571, 1995
   PubMed Web of Science ®Google Scholar
• Archer SG, Eliopoulos A, Spandidos D et al: Expression of ras p21, p53, and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266, 1995
   PubMed Web of Science ®Google Scholar
• Rosen PP, Lesser ML, Arroyo CD et al: p53 in node-negative breast carcinoma: an immunohistochemical study of epide-miologic risk factors, histologic features, and prognosis. J Clin Oncol 13:821–830, 1995
   PubMed Web of Science ®Google Scholar
• Elledge RN/I, Green S, Howes L et al: bc1-2, p53, and re-sponse to tamoxifen in ER-positive metastatic breast cancer. J Clin Oncol 15:1916–1922, 1997
   PubMed Web of Science ®Google Scholar
• Iwaya K, Tsuda H, Hiraide H et al: Nuclear p53 immunore-action associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835–840, 1991
   PubMedGoogle Scholar
• Jansson T, Inganas M, Sjogren S et al: p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13:2745–2751, 1995
   PubMed Web of Science ®Google Scholar
• Berns EMJJ, Klijn JGM, Smid M et al: TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer 16:170–179, 1996
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Benini E, Veneroni S et al: p53 and bc1-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14:1604–1610, 1996
   PubMed Web of Science ®Google Scholar
• Clarke AR, Purdie CA, Harrison DJ et al: Thymocyte apop-tosis induced by p53-dependent and independent pathways. Nature 362:849–852, 1993
   PubMed Web of Science ®Google Scholar
• Lowe SW, Ruley HE, Jacks T et al: p53-dependent apoptosis modulates the cytotoxi_city of anticancer agents. Cell 74:957–967, 1993
   PubMed Web of Science ®Google Scholar
• Lowe SW, Schmitt EM, Smith SW et al: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847–849, 1995
   Web of Science ®Google Scholar
• Elledge RM, Gray R, Mansour E et al: Accumulation of p53 protein as a possible predictor of response to adjuvant com-bination chemotherapy with cyclophosphamide, methotrex-ate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254–1256, 1995
   PubMed Web of Science ®Google Scholar
• Fan S, Smith ML, Rivet II DJ et al: Disruption of p53 func-tion sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649–1654, 1995
   PubMed Web of Science ®Google Scholar
• Shao Z-M, Dawson MI, Li XS et al: p53 independent GO/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11:493–504, 1995
   PubMed Web of Science ®Google Scholar
• Stal O, Skoog L, Rutqvist LE et al: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 70:1258–1262, 1994
   PubMed Web of Science ®Google Scholar
• Clark GM: Prognostic and predictive factors. In Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (eds). Lippincott-Raven Publishers, Philadelphia, 1996, pp 461–485
   Google Scholar
• Oncology ASoC: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843–2877, 1996
   PubMed Web of Science ®Google Scholar
• Bouzubar N, Walker KJ, Griffiths K et al: Ki-67 immuno-staining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947, 1989
   PubMed Web of Science ®Google Scholar
• Brown RW, Allred DC, Clark GM et al: Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585–592, 1996
   PubMed Web of Science ®Google Scholar
• Gaglia P, Bernardi A, Venesio T et al: Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibod-ies: its prognostic value on short term recurrences. Eur J Cancer 29A:1509–1513, 1993
   PubMed Web of Science ®Google Scholar
• Gasparini G, Boracchi P, Verderio P et al: Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immu-nocytochemistry. Int J Cancer 57:822–829, 1994
   PubMed Web of Science ®Google Scholar
• Haerslev T, Jacobsen GK, Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological pa-rameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37:101–113, 1996
   PubMed Web of Science ®Google Scholar
• Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma. Am J Clin Pathol 104:42–49, 1995
   PubMed Web of Science ®Google Scholar
• Pierga J-Y, Leroyer A, Viehl P et al: Long term prognostic value of growth fraction determination by Ki-67 immuno-staining in primary operable breast cancer. Breast Cancer Res Treat 37:57–64, 1996
   PubMed Web of Science ®Google Scholar
• Railo M, Nordling S, Von Boguslawsky K et al: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68:579–583, 1993
   PubMed Web of Science ®Google Scholar
• Rudas M, Gnant MFX, Mittlbock M et al: Thymidine label-ing index and Ki-67 growth fraction in breast cancer: com-parison and correlation with prognosis. Breast Cancer Res Treat 32:165–175, 1994
   PubMed Web of Science ®Google Scholar
• Veronese SM, Gambacorta M, Gottardi O et al: Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931, 1993
   PubMed Web of Science ®Google Scholar
• Veronese SM, Maisano C, Scibilla J: Comparative prognos-tic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 16:2717–2722, 1996
   Google Scholar
• Weikel W, Beck T, Mitze M et al: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149–154, 1991
   PubMed Web of Science ®Google Scholar
• Wintzer HO, Zipfel I, Schulte-Monting J et al: Ki-67 immu-nostaining in human breast tumors and its relationship to prognosis. Cancer 67:421–428, 1991
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Becker MHG, Key G et al: Monoclonal anti-bodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363, 1992
   PubMed Web of Science ®Google Scholar
• Horak ER, Leek R, Klenk N et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as in-dicator of node metastases and survival in breast cancer. Lancet 340:1120–1124, 1992
   PubMed Web of Science ®Google Scholar
• Bosari S, Lee AKC, DeLellis RA et al: Microvessel quanti-tation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761, 1992
   PubMed Web of Science ®Google Scholar
• Weidner N, Folkman J, Pozza F et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992
   PubMed Web of Science ®Google Scholar
• Hall NR, Fish DE, Hunt N et al: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg On-col 1(3):223–229, 1992
   Google Scholar
• Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carci-noma. hit J Cancer 55:371–374, 1993
   PubMed Web of Science ®Google Scholar
• Visscher DW, Smilanetz S, Drozdowicz S et al: Prognostic significance of image morphometric microvessel enumera-tion in breast carcinoma. Anal Quan Cytol Histol 15(2):88–92, 1993
   PubMed Web of Science ®Google Scholar
• Van Hoef MEHM, Knox WF, Dhesi SS et al: Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A(8)1141–1145, 1993
   PubMed Web of Science ®Google Scholar
• Khanuja PS, Gimotty P, Fregene T et al: Angiogenesis quan-titation as a prognostic factor for primary breast carcinoma 2 ems or less. In Adjuvant Therapy of Cancer, Salmon SE (ed). Lippincott-Raven, Philadelphia, 1993, pp 226–232
   Google Scholar
• Fox SB, Leek R, Smith K et al: Tumor angiogenesis in node-negative breast carcinoma - Relationship with epider-mal growth factor receptor, estrogen receptor and survival. Breast Cancer Res Treat 29(1):109–116, 1994
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Chung Y-S, Nakata B et al: Microvessel quanti-tation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 71:1297–1301, 1995
   PubMed Web of Science ®Google Scholar
• Obermair A, Czerwenka K, Kurz C et al: Influence of tu-moral microvessel density on the recurrence-free survival in human breast cancer: Preliminary results. Onkologie 17:44–49, 1994
   Web of Science ®Google Scholar
• Costello P, McCann A, Carney D et al: Prognostic signifi-cance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 26:1181–1184, 1995
   PubMed Web of Science ®Google Scholar
• Goulding H, Rashid NA, Robertson JF et al: Assessment of angiogenesis in breast carcinoma: An important factor in prognosis? Hum Pathol 26:1196–1200, 1995
   PubMed Web of Science ®Google Scholar
• Siitonen SM, Haapasalo HK, Rantala IS et al: Comparison of different immunohistochemical methods in the assessment of angiogenesis: Lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 8(7): 745–752, 1995
   PubMed Web of Science ®Google Scholar
• Gasparini G, Barbareschi M, Boracchi P et al: Tumor angio-genesis predicts clinical outcome of node-positive breast can-cer patients treated with adjuvant hormone therapy or che-motherapy. Cancer J Sci Am 1:131–141, 1995
   PubMedGoogle Scholar
• Macaulay VM, Fox SB, Zhang H et al: Breast cancer angio-genesis and tamoxifen resistance. Endocrine-Rel Cancer 2: 97–103, 1995.
   Web of Science ®Google Scholar
• Vermeulen PB, Libura J, Libura M et al: Re: Tumor angio-genesis as a prognostic assay for invasive ductal breast car-cinoma. J Natl Cancer Inst 87(23):1797–1798, 1995
   PubMed Web of Science ®Google Scholar
• Heimann R, Ferguson D, Powers C et al: Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88:1764–1769, 1996
   PubMed Web of Science ®Google Scholar
• Fox SB, Leek RD, Weekes MP et al: Quantitation and prog-nostic value of breast cancer angiogenesis: Comparison of microvessel density, chalkley count, and computer image analysis. J Pathol 177:275–283, 1995
   PubMed Web of Science ®Google Scholar
• Karaiossifidi H, Kouri E, Arvaniti H et al: Tumor angiogen-esis in node-negative breast cancer: Relationship with relapse free survival. Anticancer Res 16:4001–4002, 1996
   PubMed Web of Science ®Google Scholar
• Acenero MJF, Gallego MG, Ballesteros PA et al: Vascular density as a prognostic indicator for invasive ductal breast carcinoma. Virchows Arch 432:113–117, 1998
   PubMed Web of Science ®Google Scholar
• Narita M, Nakao K, Ogino N et al: Independent prognostic factors in breast cancer patients. Am J Surg 175:73–75, 1998
   PubMed Web of Science ®Google Scholar
• Toi M, Inada K, Suzuki H et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the as-sociation with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193–204, 1995
   PubMed Web of Science ®Google Scholar
• Obermair A, Kurz C, Czerwenka K et al: Microvessel density and vessel invasion in lymph-node-negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62:126–131, 1995
   PubMed Web of Science ®Google Scholar
• Axelsson K, Ljung BE, Moore DH et al: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst 87:997–1008, 1995
   PubMed Web of Science ®Google Scholar
• Honkoop AH, van Diest PJ, de Song JS et al: Prognostic role of clinical, pathological and biological characteristics in pa-tients with locally advanced breast cancer. Br J Cancer 77(4):621–626, 1998
   PubMed Web of Science ®Google Scholar
• Protopapa E, Delides GS, Revesz L: Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. Eur J Cancer 29A(10)1391–1393, 1993
   PubMed Web of Science ®Google Scholar
• Paulsen T, Aas T, Borresen A-L et al: Angiogenesis does not predict clinical response to doxorubicin monotherapy in pa-tients with locally advanced breast cancer. hit J Cancer 74: 138–140, 1997
   PubMed Web of Science ®Google Scholar
• Jacquemier JD, Penault-Llorca FM, Bertucci F et al: Angio-genesis as a prognostic marker in breast carcinoma with con-ventional adjuvant chemotherapy: A multiparametric and im-munohistochemical analysis. J Pathol 184:130–135, 1998
   PubMed Web of Science ®Google Scholar
• Gasparini G, Fox SB, Verderio P et al: Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-negative breast cancer patients. Clin Cancer Res 2:1191–1198, 1996
   PubMed Web of Science ®Google Scholar
• Page DL, Jensen RA: Angiogenesis in human breast carci-noma: What is the question? Hum Pathol 26(11):1173–1174, 1995
   PubMed Web of Science ®Google Scholar
• Vermeulen PB, Gasparini G, Fox SB et al: Quantification of angiogenesis in solid human tumours: an international con-sensus on the methodology and criteria of evaluation. Eur J Cancer 32A(14)2474–2484, 1996
   PubMed Web of Science ®Google Scholar
• Peters-Engl C, Medl M, Mirau M et al: Color-coded and spectral doppler flow in breast carcinomas - Relationship with the tumor microvasculature. Breast Cancer Res Treat 47:83–89, 1998
   PubMed Web of Science ®Google Scholar
• Peters-Engl C, Frank W, Medl M: Tumor flow in malignant breast tumors measured by doppler ultrasound: An indepen-dent predictor of survival (abstract). Breast Cancer Res Treat 50(3):228, 1998
   Google Scholar
• Holmgren L, O’Reilly MS, Folkman J: Dormancy of micro-metastases: balanced proliferation and apoptosis in the pres-ence of angiogenesis suppression. Nat Med 1:149–153, 1995
   PubMed Web of Science ®Google Scholar
• Folkman J: Clinical applications of research on angiogenesis. New Eng J Med 333(26):1757–1763, 1995
   PubMed Web of Science ®Google Scholar
• Harris AL, Zhang H, Moghaddam A et al: Breast cancer angiogenesis - new approaches to therapy via antiangiogen-esis, hypoxic activated drugs, and vascular targeting. Breast Cancer Res Treat 38:97–108, 1996
   PubMed Web of Science ®Google Scholar
• Harris JR, Hellman S: Natural history of breast cancer. In Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (eds). Lippincott-Raven Publishers, Philadelphia, 1996, pp 375–391
   Google Scholar
• Saphir O, Amromin GD: Obscure axillary lymph-node me-tastasis in carcinoma of the breast. Cancer 1:238–241, 1948
   PubMed Web of Science ®Google Scholar
• Sloane JP, Ormerod M, Imrie SF et al: The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer 42(3):392–398, 1980
   PubMed Web of Science ®Google Scholar
• Pickren JW: Significance of occult metastases: A study of breast cancer. Cancer 14:1266–1271, 1961
   PubMed Web of Science ®Google Scholar
• Huvos AG, Hutter RVP, Berg JW: Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 173(1):44–46, 1971
   PubMed Web of Science ®Google Scholar
• Attiyeh FF, Jensen M, Huvos AG et al: Axillary microme-tastases and macrometastases in carcinoma of the breast. Surg Gynecol Obstet 144(6):839–842, 1977
   PubMedGoogle Scholar
• Fisher ER, Swamidoss S, Lee CH et al: Detection and sig-nificance of occult axillary node metastases in patients with invasive breast cancer. Cancer 42:2025–2031, 1978
   PubMed Web of Science ®Google Scholar
• Black RB, Roberts M, Stewart HJ et al: The search for occult metastases in breast cancer: does is add to established staging methods? Aust N Z J Surg 50(6):574–579, 1980
   PubMedGoogle Scholar
• Rosen PP, Saigo PE, Braun DW et al: Axillary micro- and macrometastases in breast cancer. Ann Surg 194(5):585–591, 1981
   PubMed Web of Science ®Google Scholar
• Rosen PP, Saigo P, Braun DWJ et al: Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumor emboli. Am J Surg Pathol 6(7):639–641, 1982
   PubMed Web of Science ®Google Scholar
• Wilkinson EJ, Hause L, Hoffman RG et al: Occult axillary lymph node metastases in invasive breast carcinoma: char-acteristics of the primary tumor and significance of the me-tastases. Pathol Annu 17(Pt (2))67–91, 1982
   Google Scholar
• Wells CA, Heryet A, Brochier J et al: The immunohisto-chemical detection of axillary micrometastases in breast can-cer. Br J Cancer 50(2):193–197, 1984
   PubMedGoogle Scholar
• Bussolati G, Gugliotta P, Mona I et al: The immunohisto-chemical detection of lymph node metastases from infiltrat-ing lobular carcinoma. Br J Cancer 54(4):631–636, 1986
   PubMed Web of Science ®Google Scholar
• Trojani M, de Mascarel I, Bonichon F et al: Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer 1987(55):303–306, 1987
   PubMedGoogle Scholar
• Byrne J, Waldron R, McAvinchey D et al: The use of mono-clonal antibodies for the histopathological detection of mam-mary axillary micrometastases. Eur J Surg Oncol 13(5):409–411, 1987
   PubMedGoogle Scholar
• Friedman S, Bertin F, Mouriesse H et al: Importance of tumor cells in axillary node sinus margins (clandestine me-tastases) discovered by serial sectioning in operable breast cancer. Acta Oncol 27(5):483–487, 1988
   PubMed Web of Science ®Google Scholar
• Berry N, Jones D, Marshall R et al: Comparison of the de-tection of breast carcinoma metastases by routine histological diagnosis and by immunohistochemical staining. Eur Surg Res 20(4):225–232, 1988
   PubMed Web of Science ®Google Scholar
• Sedmak DD, Meinke T, Knechtges DS: Detection of meta-static breast carcinoma with monoclonal antibodies to cyto-keratins. Arch Pathol Lab Med 113:786–789, 1989
   PubMed Web of Science ®Google Scholar
• Apostolikas N, Petraki C, Agnantis AG: The reliability of histologically negative axillary lymph nodes in breast cancer. Pathol Res Pract 184:35–38, 1988
   PubMed Web of Science ®Google Scholar
• Raymond WA, Leong A-Y: Immunoperoxidase staining in the detection of lymph node metastases in stage I breast cancer. Pathol 21:11–15, 1989
   PubMed Web of Science ®Google Scholar
• International (Ludwig) Breast Cancer Study Group: Prognos-tic importance of occult axillary lymph node micrometasta-ses from breast cancers. Lancet 335:1565–1568, 1990
   PubMed Web of Science ®Google Scholar
• Springall RJ, Rytina E, Millis RR: Incidence and significance of micrometastases in axillary lymph nodes detected by im-munohistochemical techniques. J Pathol 160:174A, 1990
   Web of Science ®Google Scholar
• Galea MH, Athanassiou E, Bell J et al: Occult regional lymph node metastases from breast carcinoma. Immunohis-tochemical detection with antibodies CAM 5.2 and NCRC-11. J Pathol 165(3):221–227, 1991
   PubMed Web of Science ®Google Scholar
• Chen Z-L, Wen D-L, Coulson WF et al: Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histological examination and con-ventional histology. Dis Markers 9(5):239–248, 1991
   PubMed Web of Science ®Google Scholar
• Byrne J, Horgan P, England SS et al: A preliminary report on the usefulness of monoclonal antibodies to CA 15–3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast cancer. Eur J Cancer 28(2): 658–660, 1992
   PubMedGoogle Scholar
• de Mascarel I, Bonichon F, Coindre JM et al: Prognostic significance of breast cancer axillary lymph node microme-tastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 66:523–527, 1992
   PubMed Web of Science ®Google Scholar
• Clayton F, Hopkins CL: Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 71:1780–1790, 1993
   PubMed Web of Science ®Google Scholar
• Hainsworth PJ, Tjandra JJ, Stillwell RG et al: Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 80:459–463, 1993
   PubMed Web of Science ®Google Scholar
• Elson CE, Kufe D, Johnston WW: Immunohistochemical detection and significance of axillary lymph node microme-tastases in breast carcinoma. A study of 97 cases. Anal Quan Cytol Histol 15(3):171–178, 1993
   PubMed Web of Science ®Google Scholar
• Nasser IA, Lee AKC, Bosari S et al: Occult axillary lymph node metastases in node-negative breast carcinoma. Hum Pathol 24:950–957, 1993
   PubMed Web of Science ®Google Scholar
• McGuckin MA, Cummings MC, Walsh MD et al: Occult axillary node matastases in breast cancer: their detection and prognostic significance. Br J Cancer 73(1):88–95, 1996
   PubMed Web of Science ®Google Scholar
• Zhang PJ, Reisner RM, Nangia R et al: Effectiveness of multiple-level sectioning in detecting axillary nodal micro-metastasis in breast cancer. Arch Pathol Lab Med 122:687–690, 1998
   PubMed Web of Science ®Google Scholar
• Krag D, Weaver D, Ashikaga T et al: The sentinel node in breast cancer: A multicenter validation study. New Eng J Med 339(14):941–946, 1998
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Kirgan DM, Guenther JM et al: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391–398, 1994
   PubMed Web of Science ®Google Scholar
• Alex JC, Krag DN: The gamma-probe-guided resection of radiolabeled primary lymph nodes. Surg Oncol Clin North Am 5:33–41, 1996
   Google Scholar
• Albertini JJ, Lyman GH, Cox C et al: Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818–1822, 1996
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Jones RC, Brennan M et al: Sentinel lymph-adenectomy in breast cancer. J Clin Oncol 15:2345–2350, 1997
   PubMed Web of Science ®Google Scholar
• Borgstein PJ, Meijer S, Pijpers R: Intradermal blue dye to identify sentinel lymph-node in breast cancer. Lancet 349: 1668–1669, 1997
   PubMed Web of Science ®Google Scholar
• Barnwell JM, Arrendondo MA, Kollmorgen D et al: Sentinel node biopsy in breast cancer. Ann Surg Oncol 5:126–130, 1998
   PubMed Web of Science ®Google Scholar
• Veronesi U, Paganelli G, Galimberti V et al: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clini-cally negative lymph-nodes. Lancet 349:1864–1867, 1997
   PubMed Web of Science ®Google Scholar
• Guenther JM, Krishnamoorthy M, Tan LR: Sentinel lymph-adenectomy for breast cancer in a community managed care setting. Cancer J Sci Am 3:336–340, 1997
   Google Scholar
• Borgstein PJ, Pijpers R, Comans EF et al: Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lym-phoscintigraphy and gamma probe detection. J Am Coll Surg 186:275–283, 1998
   PubMed Web of Science ®Google Scholar
• Crossin JA, Johnson AC, Stewart PB et al: y-probe-guided resection of sentinel lymph node in breast cancer. Am Surg 64:666–668, 1998
   PubMed Web of Science ®Google Scholar
• Berger U, Bettelheim R, Mansi IL et al: The relationship between micrometastases in the bone marrow, histopatholog-ic features of the primary tumor in breast cancer and prog-nosis. Am J Clin Pathol 90(1):1–6, 1988
   PubMed Web of Science ®Google Scholar
• Kirk SJ, Cooper GG, Hoper M et al: The prognostic signifi-cance of marrow micrometastases in women with early breast cancer. Eur J Surg Oncol 16:481–485, 1990
   PubMed Web of Science ®Google Scholar
• Salvadori B, Squicciarini P, Rovini D et al: Use of mono-clonal antibody MBrl to detect micrometastases in bone marrow specimens of breast cancer, patients. Eur J Cancer 26(8):865–867, 1990
   PubMed Web of Science ®Google Scholar
• Cote RJ, Rosen PP, Lesser M et al: Prediction of early re-lapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 9(10): 1749–1756, 1991
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Ormerod MG, Sloane JP: Micrometastases in breast cancer: Long term follow-up of the first patient cohort. Eur J Cancer 27:236–239, 1991
   PubMed Web of Science ®Google Scholar
• Mansi JL, Easton D, Berger U et al: Bone marrow micro-metastases in primary breast cancer: prognostic significance after 6 years follow-up. Eur J Cancer 27(12):1552–1555, 1991
   PubMed Web of Science ®Google Scholar
• Singletary SE, Larry L, Tucker SL et al: Detection of micro-metastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 47(1):32–36, 1991
   PubMed Web of Science ®Google Scholar
• Courtemanche DJ, Worth AJ, Coupland RW et al: Monoclo-nal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer. Can J Surg 34(1):21–26, 1991
   PubMed Web of Science ®Google Scholar
• Harbeck N, Untch M, Pache L: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 69:566–571, 1994
   PubMed Web of Science ®Google Scholar
• Diel IJ, Kaufman M, Costa SD et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1664, 1996
   PubMed Web of Science ®Google Scholar
• Molino A, Pelosi G, Turazza M et al: Bone marrow micro-metastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis. Breast Can-cer Res Treat 42(1):23–30, 1997
   PubMed Web of Science ®Google Scholar